News

Novo Nordisk's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...
EU Drug Regulator Finds ‘Very Rare’ Ozempic Link to Vision Loss
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
MedPage Today on MSN1d
GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns
A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
EMA says Ozempic, Wegovy may cause rare eye condition
The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
BioSpace1d
EU Regulators Confirm Rare Vision Loss Risk for Novo’s Semaglutide
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...
The New York Sun1d
Popular Weight-Loss Drugs Ozempic, Wegovy Linked to Dangerous Eye Condition
Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...
India Today1d
European drugs regulator flags rare eye risk with Ozempic
The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...
Morningstar2d
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory ...